Publications by authors named "Y-Y Chang"

Purpose: To compare clinical outcomes and retear rates of medium-sized rotator cuff tears repaired with incomplete footprint coverage using the transosseous-equivalent technique versus those with complete footprint coverage plus bone marrow stimulation.

Methods: The retrospective study, conducted from March 2019 to December 2021, included consecutive patients with medium-sized (1-3 cm) posterosuperior rotator cuff tears repaired using the transosseous-equivalent technique and bone marrow stimulation, with a minimum follow-up of 2 years. Patients were divided into 2 groups based on the degree of footprint coverage achieved: group C (complete coverage) and group I (incomplete coverage).

View Article and Find Full Text PDF

Background: Currently, there is no consensus on how to comprehensively assess comorbidities in lung cancer patients in the clinical setting. Prescription medications may be a preferred comorbidity assessment tool and provide a simple mechanism for predicting postoperative outcomes for lung cancer. We examined the relationship between prescription medications and postoperative outcomes for early-stage non-small cell lung cancer (NSCLC).

View Article and Find Full Text PDF

Purpose To develop a deep learning model for the morphologic measurement of unruptured intracranial aneurysms (UIAs) based on CT angiography (CTA) data and validate its performance using a multicenter dataset. Materials and Methods In this retrospective study, patients with CTA examinations, including those with and without UIAs, in a tertiary referral hospital from February 2018 to February 2021 were included as the training dataset. Patients with UIAs who underwent CTA at multiple centers between April 2021 to December 2022 were included as the multicenter external testing set.

View Article and Find Full Text PDF
Article Synopsis
  • Biallelic loss of CDK12 is linked to a specific subtype of metastatic castration-resistant prostate cancer (mCRPC), raising questions about its role in cancer development versus exposing drug targets.
  • Research shows that loss of CDK12 leads to early cancer-like changes and enhances cancer cell growth when combined with mutations in other genes like Trp53, while it inhibits tumor growth in the absence of another tumor suppressor gene, Pten.
  • CDK12 loss causes genomic instability and makes tumors sensitive to treatments targeting another protein, CDK13, highlighting CDK12 as a crucial tumor suppressor and suggesting new therapeutic approaches for CDK12-mutant mCRPC.
View Article and Find Full Text PDF

Cyclin-dependent kinases 12/13 play pivotal roles in orchestrating transcription elongation, DNA damage response, and maintenance of genomic stability. Biallelic CDK12 loss has been documented in various malignancies. Here, we develop a selective CDK12/13 PROTAC degrader, YJ9069, which effectively inhibits proliferation in subsets of prostate cancer cells preferentially over benign immortalized cells.

View Article and Find Full Text PDF
Article Synopsis
  • - The study examined the use of the modified pouchitis disease activity index (mPDAI) to assess symptoms and endoscopic findings among different pouchitis phenotypes in inflammatory bowel disease (IBD).
  • - A total of 103 IBD patients were analyzed, revealing that patients with normal pouches had a median mPDAI of 0, while those with cuffitis had the highest median score of 4.0, indicating more severe symptoms.
  • - The findings suggested that the mPDAI may have limited effectiveness in differentiating between various inflammatory phenotypes, prompting the need for further research to identify which symptoms should be monitored.
View Article and Find Full Text PDF

Background: Cardiocerebral infarction (CCI), which is concomitant with acute myocardial infarction (AMI) and acute ischemic stroke (AIS), is a rare but severe presentation. However, there are few data on CCI, and the treatment options are uncertain. We investigated the characteristics and outcomes of CCI compared with AMI or AIS alone.

View Article and Find Full Text PDF

Background: Chimeric antigen receptor (CAR)-T cell therapies targeting glioblastoma (GBM)-associated antigens such as interleukin-13 receptor subunit alpha-2 (IL-13Rα2) have achieved limited clinical efficacy to date, in part due to an immunosuppressive tumor microenvironment (TME) characterized by inhibitory molecules such as transforming growth factor-beta (TGF-β). The aim of this study was to engineer more potent GBM-targeting CAR-T cells by countering TGF-β-mediated immune suppression in the TME.

Methods: We engineered a single-chain, bispecific CAR targeting IL-13Rα2 and TGF-β, which programs tumor-specific T cells to convert TGF-β from an immunosuppressant to an immunostimulant.

View Article and Find Full Text PDF

Assessing programmed death ligand 1 (PD-L1) expression through immunohistochemistry (IHC) is the golden standard in predicting immunotherapy response of non-small cell lung cancer (NSCLC). However, observation of heterogeneous PD-L1 distribution in tumor space is a challenge using IHC only. Meanwhile, immunofluorescence (IF) could support both planar and three-dimensional (3D) histological analyses by combining tissue optical clearing with confocal microscopy.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the effectiveness and tolerability of two treatments for chronic migraine: CGRP monoclonal antibodies (mAbs) and onabotulinumtoxinA.
  • It included 649 chronic migraine patients and found that CGRP mAbs reduced monthly migraine days more significantly than onabotulinumtoxinA and had a higher responder rate.
  • Both treatments were well-tolerated, with fewer adverse events reported for CGRP mAbs, but further studies are needed to confirm these results.
View Article and Find Full Text PDF

Circulating tumor DNA (ctDNA) is emerging as a potential biomarker in early-stage urothelial cancer, but its utility in metastatic disease remains unknown. In the phase 3 KEYNOTE-361 study, pembrolizumab with and without chemotherapy was compared with chemotherapy alone in patients with metastatic urothelial cancer. The study did not meet prespecified efficacy thresholds for statistical significance.

View Article and Find Full Text PDF

Background: Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation (HSCT) has the potential for long-term tumor elimination. However, pre-HSCT myeloablation and graft-versus-host disease (GVHD) prophylaxis agents have toxic effects and could eradicate residual CAR T cells and compromise antitumor effects.

View Article and Find Full Text PDF
Article Synopsis
  • Biallelic loss of the gene encoding cyclin-dependent kinase 12 (CDK12) is linked to a distinct type of advanced prostate cancer, known as metastatic castration-resistant prostate cancer (mCRPC), though its role in cancer development and treatment response is still being investigated.
  • Research using mouse models shows that loss of CDK12 can lead to early-stage cancer changes and increased immune response, as well as promote tumor growth in lab settings when paired with other genetic modifications.
  • CDK12 mutations make tumors more responsive to certain immunotherapies and therapies targeting related kinases, suggesting that CDK12 acts as a tumor suppressor and emphasizing the potential for new treatment strategies focusing on related gene interactions in mutant m
View Article and Find Full Text PDF

Improvements in survival have been made over the past two decades for childhood acute myeloid leukemia (AML), but the approximately 40% of patients who relapse continue to have poor outcomes. A combination of checkpoint-inhibitor nivolumab and azacitidine has demonstrated improvements in median survival in adults with AML. This phase I/II study with nivolumab and azacitidine in children with relapsed/refractory AML (NCT03825367) was conducted through the Therapeutic Advances in Childhood Leukemia & Lymphoma consortium.

View Article and Find Full Text PDF

Introduction: This post hoc analysis evaluated the efficacy of tenapanor on abdominal symptoms in patients with irritable bowel syndrome with constipation. Abdominal symptoms assessed included pain, discomfort, bloating, cramping, and fullness.

Methods: The abdominal symptom data were pooled from 3 randomized controlled trials (NCT01923428, T3MPO-1 [NCT02621892], and T3MPO-2 [NCT02686138]).

View Article and Find Full Text PDF

Background: Lung function is routinely assessed prior to surgical resection for non-small cell lung cancer (NSCLC). Further assessment of chronic obstructive pulmonary disease (COPD) using inhaled COPD medications to determine disease severity, a readily available metric of disease burden, may predict postoperative outcomes and overall survival (OS) in lung cancer patients undergoing surgery.

Methods: We retrospectively evaluated clinical stage I NSCLC patients receiving surgical treatment within the Veterans Health Administration from 2006-2016 to determine the relationship between number and type of inhaled COPD medications (short- and long-acting beta2-agonists, muscarinic antagonists, or corticosteroids prescribed within 1 year before surgery) and postoperative outcomes including OS using multivariable models.

View Article and Find Full Text PDF

Background: Pathogenic variants in can result in long QT syndrome type 3, a life-threatening genetic disease. Adenine base editors can convert targeted A T base pairs to G C base pairs, offering a promising tool to correct pathogenic variants.

Methods: We generated a long QT syndrome type 3 mouse model by introducing the T1307M pathogenic variant into the gene.

View Article and Find Full Text PDF

Background: Few studies have measured ventilation during early cardiopulmonary resuscitation (CPR) before advanced airway placement. Resuscitation guidelines recommend pauses after every 30 chest compressions to deliver ventilations. The effectiveness of bag-valve-mask ventilation delivered during the pause in chest compressions is unknown.

View Article and Find Full Text PDF

RET receptor tyrosine kinase is activated in various cancers (lung, thyroid, colon and pancreatic, among others) through oncogenic fusions or gain-of-function single-nucleotide variants. Small-molecule RET kinase inhibitors became standard-of-care therapy for advanced malignancies driven by RET. The therapeutic benefit of RET inhibitors is limited, however, by acquired mutations in the drug target as well as brain metastasis, presumably due to inadequate brain penetration.

View Article and Find Full Text PDF
Article Synopsis
  • Ulcerative colitis (UC) and Crohn's disease are forms of inflammatory bowel disease (IBD) caused by abnormal immune responses, and the study focuses on the less understood interactions among immune cells and the mechanisms behind the drug vedolizumab.
  • Researchers used a method called CITE-seq on immune cells from UC patients treated with vedolizumab and applied a computational tool (NicheNet) to study immune cell interactions and transcriptional changes.
  • Findings showed that UC patients who responded to vedolizumab had fewer T helper 17 (TH17) cells and different interaction patterns with other immune cells compared to nonresponders, suggesting that understanding cell communications could enhance treatments for IBD.
View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating cancer due to its poor survival rate, early detection, and resectability. This study aimed to determine the peripheral blood mononuclear cell (PBMC) immune biomarkers in patients with PDAC and investigate the PDAC-specific peripheral blood biomarker panel and validate its clinical performance.

Methods: In this prospective, blinded, case-control study, a biomarker panel formula was generated using a development cohort-including healthy controls, patients at high risk of PDAC, and patients with benign pancreatic disease, PDAC, or other gastrointestinal malignancies-and its diagnostic performance was verified using a validation cohort, including patients with ≥ 1 lesion suspected as PDAC on computed tomography (CT).

View Article and Find Full Text PDF
Article Synopsis
  • - Nirsevimab is a monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) by maintaining high levels of neutralizing antibodies (NAbs) after administration, as shown in the MELODY clinical trials.
  • - Analysis of over 2,000 infants revealed that preterm infants had lower baseline RSV antibody levels compared to full-term infants, but nirsevimab significantly boosted NAb levels, remaining high for up to a year.
  • - Despite its protective effects against RSV, nirsevimab still allowed infants to develop their immune response to the virus, indicating it can both prevent RSV disease and promote future immunity.
View Article and Find Full Text PDF

Background: Elevated blood pressure and intrarenal renin-angiotensin system activity are closely related to chronic kidney disease (CKD) progression. However, interrelationship between blood pressure and intrarenal renin-angiotensin system activity on the risk of CKD progression is unknown.

Methods: We analyzed 2076 participants from the Korean Cohort Study for Outcomes in Patients With CKD.

View Article and Find Full Text PDF

Background: Vascular aging, as assessed by structural and functional arterial properties, is an independent predictor of cardiovascular outcomes. We aimed to explore the associations of individual cardiovascular risk factors from childhood to midlife and their accumulation over a 30-year span with vascular aging in midlife.

Methods: Using data from the ongoing cohort of Hanzhong Adolescent Hypertension study, 2180 participants aged 6 to 18 years at baseline were followed for over 30 years.

View Article and Find Full Text PDF

The association between loss of BRCA1/2 and a homologous recombination deficiency phenotype is lineage dependent. In BRCA-associated cancers such as breast, ovarian, pancreas and prostate, this phenotype confers sensitivity to PARP inhibitors and platinum-therapies. Somatic reversion mutations restoring BRCA1/2 function mediate resistance, and have exclusively been reported in BRCA-associated tumors.

View Article and Find Full Text PDF